Merck's sac-TMT extends survival in advanced stomach and esophageal cancer trial
Merck says its experimental sac-TMT improved overall survival versus chemotherapy in a late-stage trial, though it missed a secondary progression goal.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Merck said on Friday that its experimental cancer drug sacituzumab tirumotecan, or sac-TMT, helped patients with advanced stomach and esophageal cancer live longer than standard treatment in a late-stage trial. The study enrolled 473 patients whose tumors could not be removed surgically and whose disease had progressed after at least two earlier therapies. Physicians chose the comparison chemotherapy from trifluridine-tipiracil, irinotecan, paclitaxel or docetaxel.
The trial did not meet its secondary goal of delaying disease progression, as measured by an independent reviewer. Merck has not released detailed data yet and plans to present it at a future medical meeting. The company said the drug raised no new safety concerns. Merck licensed sac-TMT from China's Kelun-Biotech for markets outside Greater China and is testing it in lung, breast and gastrointestinal tumors.
why it matters
This is mainly a pipeline update for Merck rather than a broad market event. Investors will look for the detailed survival figures and the safety profile, which will determine how much weight sac-TMT carries in the company's oncology portfolio.
tags
instruments
on polymarket
sources
- Merck's drug prolongs survival in advanced stomach, esophageal cancers in trial — Reuters, 20 November 2026 at 12:37 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗